Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma.

CONCLUSIONS: Curative resection was achieved for about 40% of the patients who received NACRT for BR-ESCC. Therefore, NACRT could be a useful neoadjuvant treatment option for BR-ESCC. However, a higher serum SCC antigen level before NACRT is predictive of treatment failure and poor survival. PMID: 31820213 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31820213?dopt=Abstract

Source: Ann Oncol - December 8, 2019 Category: Cancer & Oncology Authors: Suzuki T, Okamura A, Watanabe M, Mine S, Imamura Y, Asari T, Osumi H, Nakayama I, Ichimura T, Ogura M, Ooki A, Takahari D, Yamaguchi K, Chin K Tags: Ann Surg Oncol Source Type: research